In 935 patients with resected non-small cell lung cancer, adjuvant nivolumab for up to 1 year did not improve disease-free survival vs observation (median 71.3 vs 68.8 months; HR 0.97), nor in PD-L1 ≥50% (HR 0.86). Stopped for futility.
RCTn = 935
Chaft et al. Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial